cardiovascular outcomes

Multidomain Rehabilitation Reduces Cardiovascular Events in Older Adults Post-Myocardial Infarction: Insights from the PIpELINe Trial

By MedXY 09/10/2025

A multidomain rehabilitation program combining cardiovascular risk control, dietary counseling, and exercise significantly lowers the risk of cardiovascular death or unplanned hospitalization within one year in older myocardial infarction survivors with impaired physical performance.

Clinical Updates Wellness & Lifestyle

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

By MedXY 09/06/2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and atherosclerotic cardiovascular disease.

Clinical Updates Wellness & Lifestyle

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

By MedXY 08/27/2025

This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone's efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing future directions for mineralocorticoid receptor antagonism in this population.

Clinical Updates Wellness & Lifestyle

Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis

By MedXY 08/27/2025

The ALCHEMIST trial reveals spironolactone does not improve cardiovascular outcomes in high-risk chronic haemodialysis patients, aligning with a meta-analysis that challenges the benefit of mineralocorticoid receptor antagonists in this population.

Clinical Updates Wellness & Lifestyle

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

By MedXY 08/24/2025

The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.

Clinical Updates Wellness & Lifestyle

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY 08/17/2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Clinical Updates Wellness & Lifestyle

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Clinical Updates Wellness & Lifestyle

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans

By MedXY 08/02/2025

The MISSION Act reduced travel times to cardiac procedures for veterans distant from VA centers but was linked to higher short-term adverse cardiovascular events for PCI and CABG, highlighting complex trade-offs in access and care quality.